FAST Forward

Disease site: Breast Cancer

Treatment Modality: Radiotherapy

Status: Open to recruitment

The FAST-Forward trial is a randomised controlled multi-centre clinical trial that aims to identify a 5-fraction schedule of curative radiotherapy delivered in 1 week that is at least as effective and safe as the UK standard 15-fraction regimen after primary surgery for early breast cancer. Patients are randomised to 15 or 5 daily fractions (Fr) to the whole breast or post-mastectomy chest wall. A sequential tumour bed boost may be added after breast conservation surgery, but dose level (10 Gy or 16 Gy in 2.0 Gy Fr) must be declared before randomisation. Each patient will be allocated to one of the following groups:

Control: 40.05 Gy in 15 Fr of 2.67 Gy
Test 1:   27.0 Gy in 5 Fr of 5.4 Gy
Test 2:   26.0 Gy in 5 Fr of 5.2 Gy

Primary endpoint: ipsilateral local tumour control
Secondary endpoints: early and late adverse effects in normal tissues, quality of life, contralateral primary tumours, regional and distant metastases and survival.

Chief Investigator:        Professor John Yarnold

Sponsor:                         The Institute of Cancer Research

Source of Funding:         National Institute for Health Research- Health Technology Assessment Programme (11/LO/0958)

ISRCTN:                        19906132

Trial Office Contact      

Trial Manager: Mark Sydenham
Phone: 020 8722 4104  |  Email: Fastforward-icrctsu@icr.ac.uk

Further information on the FAST-Forward trial may be found on the following site:
Current recruitment level at the UKCRN Portfolio